1

Max India Limited

Investor PresentationJanuary 2009

BSE Scrip Code: 500271, NSE Ticker: MAX, Bloomberg: MAX:INwww.maxindia.com

2

VISION“To be one of India’s most admired corporates for service excellence”

Max India – An Introduction

Life Insurance

Protecting Life

HealthcareCaring for Life

Clinical Research

Improving Life

Health Insurance*

Enhances Life

* JV agreement signed on September 3, 2008. Statutory approvals in process.

Multi-business corporate I Focused on people and service

“ IN THE BUSINESS OF LIFE ”

3

Our Other Business

ManufacturingNiche high barrier polymer films & Leather Finishing Foils.

Focus on healthcare, children and the environment.

Corporate Social Responsibility

Max India – An Introduction

4

Max India Group – Key Highlightsn A leading conglomerate of repute in India

Life Insurance – 74:26 JV with New York Life

Healthcare – 70% owned. 8 healthcare facilities with 800 Beds

Clinical Research – 100% owned. 250+ active sites

Speciality Packaging – capacity of 29,000 TPA. 100% utilization

Health Insurance – JV with BUPA Finance Plc, UK

n 3 Million Customers… 20,000 Employees… 72,000 Agents… 1,200 Doctors…

n Track record of successful international business partnerships over last 20 years

Pharmaceuticals Electronic Component

Mobile Telephony

CommunicationServices Plating Chemicals Medical

Transcription

Hutchison COMSAT ATOTECH

5

Consolidated Performance Snapshot(Rs. Crore)

CONSOLIDATED FINANCIAL HIGHLIGHTS

Details 9M’FY09

Growth

Y-o-Y

(%)

FY’07-08

Growth

Y-o-Y

(%)

Operating Revenue 3,194 49% 3,244 78%

Investment and Other Income* 290 -54% 367 110%

Total Revenue 3484 26% 3,611 81%

Net Income Before Tax** (350) - (43) -

Net Worth 1,278 1,537

Preference Shares 250 250

Loans Funds 359 552

Fixed Assets (Net Block) 898 718

Treasury Corpus 390 1,261

Life Insurance Investments (AUM) 4,827 3,575

7001,111

1,994

3,611 3,484

* Investment & other Income is lower because of downturn in capital markets and utilization of treasury corpus to fund expansion plans of the group.** Losses have increased on account of significant expansion being undertaken in the life insurance business.

6

FDI –Warburg Pincus13.4%

Max India – Shareholding

FII – Warburg Pincus9.1%

FII – Others27.7%

Others15.2%

Number of Outstanding Shares - 222,030,310

Promoter Group –Analjit Singh

34.6%

As on Dec 31, 2008

7

n Joint-venture with BUPA Finance Plc., UK, world leader of highest

pedigree in this space

n Max India to hold 50% in the joint-venture

n Management team in place

n Currently in the process of seeking regulatory approvals

n Market roll-out by fourth quarter of 2009

n Initial capital of Rs. 100 Crore; peak capital commitment Rs 400 -

450 Crore

Max India to foray into Health Insurance…

US$ 1 = INR 49

8

Max New York Life Insurance [ MNYL ]

www.maxnewyorklife.com

9

n Joint Venture between Max India and New York Life, a fortune 100 company witharound $280 billion in assets under management

n Max India and NYL jointly drive growth strategy

n Max provides Indian industry perspective and manages the regulatory environment

n Peak equity commitment around Rs. 3,800 Crore; Rs. 1,782 Crore already infused

Max New York Life Insurance [ MNYL ]

10

India’s Life Insurance Industry has shown strong growth

Growth driven by…n Strong GDP growth (Average of 8.9% since last four years)

n Low insurance penetration (4% of GDP as against over 8% in developed countries)

n Aggressive distribution expansion by private players (Over 5000 new offices in 4 years)

n Favorable demographics (working population, aged 15-64 yrs, is over 60%)

n Product Innovation (Unit Linked products, Health & Pension)

Individual Adjusted Premium (Individual Non-Single Premium + 10% of Individual Single Premium)

11

Industry growth rate have moderated

Source: IRDA website* MNYL Internal Estimates and analysts reports

Expected Growth over next five years …n Private players expected to grow at a CAGR of ~25% from FY 2008 to FY 2012 *

n Life Insurance penetration to be around 5% of GDP by FY 2012 Vs 4% now *

Pvt. Players 18%

MNYL 42%

LIC - 28%

12

Market PositionInsurance Sales (Rs. Crore)

Source: Insurance Regulatory & Development Authority, Adjusted to include only 10% of Single PremiumAll Others include: ING Vysya, Aviva, Shriram, Bharti AXA, Sahara, IDBI Fortis, Future Generali, Canara HSBC OBC and Aegon Religare

CompanyIndividual New Business

PremiumIndividual Policies

ICICI Prudential 6,684 2,914Bajaj Allianz 5,642 3,745

HDFC Standard Life

1,873 1,074

Max New York Life 1,308 874

Met LifeKotak Life

2,653 926Reliance Life

1,976

235

All Others

767

1,046

Total Private Life Insurers 26,570 13,262

MS of Private Players (%) 50 26

61,712 688

SBI Life

946 3147

Tata AIG 497793

(FY 2007-08)

3,6462,6801,955

1,185

1,877

1,573

663

18,238

60

1,606

7887

594

(Apr-Dec’08)(‘000)

(FY 2007-08)(Apr-Dec’08)

1,8821,8081,355

900

598

191

885

9,947

32

4812

394

479

2,216 949Birla Sunlife

1,671 643

13

n Multi-channel distribution strategyHighly productive agency model (Over double the average productivity ofprivate players)Strong non-agency relationships contributing to over 36% of sales in 9M’08-09

n Comprehensive product suite across all market segmentsStrong traditional products portfolioComprehensive Unit Link product suiteRecently launched Health and Retirement products

n Best in class training capabilities (over 850 trainers on board)Advise based insurance sales by AgencyDetailed need analysis

n Long tenor products and young customer base

n Conservation ratio* of 85% in 9M’08-09 against 83% in FY 07-08

n Scalability of IT and administration systems

n Strong management team with proven execution capabilities

MNYL Key Differentiators

* Conservation ratio is defined as Current Period Renewal premium / (Last Period Renewal Premium + Last Period Regular Business Premium)

14

n Golden Peacock Innovation Award 2008 for Max Vijay

n Grant of US$ 400K from International Labour Organization (ILO) for MaxVijay

n 7th best company to work for in India by Mercer Business Today Survey

n CIO 100 Award for innovation in technology implementation

n CII Business Excellence commendation for “Strong Commitment toExcel”

n Outlook Money ranked MNYL # 1 in Slow, Medium and Quick fundcategory

MNYL – Rewards & Recognition

15

MNYL – The Leading Agency Sales Force

Source: IRDA Journal, media reports and company’s internal estimates

Adjusted Single premium

446 59,000 8,393 0.68

835 116,000 8,000 0.40

1,564 159,000 10,928 0.76

265 42,500 6,929 0.20

433 38,000 12,672 0.63

231 36,000 7,138 0.40

2,261 274,500 9,151 0.47

1,002 166,500 6,690 0.26

325 55,314 6,521 0.36

•In terms of highest new business premium (Agency)** Average agents

938 52,500 19,860 0.63

817 54,448 16,679 1.15

2,063 270,000 8,491 0.57

2

4

7

3

1

6

5

89

12

11

10

1

2

3

4

4

5

6

77

8

9

10

New Business Apr – Dec ‘08

(Agency) (Rs. Crore)Agents** Premium per

Agent * (Rs.)Cases per Agent *Rank Rank

16

MNYL Focus… Protection Oriented, Longer Tenor Life Insurance

33

28

32

0.3DEFERRED ANNUITY

8.4MONEY BACK

UNIT LINKED 54.5

3.4TERM

17.7WHOLE LIFE

PROPORTION OF POLICIES (%, by

number)

PRODUCT TYPETenure (Years)

Age of Insured(Years)

22 34MNYL Average MNYL Average

18

26

44

36

3617

16

40

ENDOWMENT 11.9 22

As on Dec 31, 2008

HEALTH 3.7 3513

17

MNYL – Embedded Value 2007-08

Amount in Rs. Crore

Unwind of discount

Opening EV

Value ofNew

Business

Other adjustment

New Capital Injection

Closing EV

Denotes decrease to EV

Denotes increase to EV

267

102

Operating Variance

22

300

10

1,316

Maintenance Expense Overrun

35

Implied NBM is 20.4%

on APE*

*APE – Adjusted Premium Equivalent (First Year Premium adjusted for 10% of Single Premium)

464

206

362

954

Net WorthValue of Inforce business

670

18

Economic Assumptions

Sensitivityn For change in risk discount rate by 0.25%, the value of new business would

change by 1.89%

Operating Assumptionsn Operating assumptions like mortality, morbidity and lapses are based on our own

experience and validated with industry / reinsurers experience.

n Expense assumptions are based on our own expense projection model. Basis ourcurrent expansion strategy, our expense break even happens in year FY 11-12

MNYL – Key Assumptions to Embedded Value

Particulars AssumptionsCash/Money Market/TB 6.50%G Secs 8.00%Corporate Bonds 8.95%Equities 13.00%Inflation 6.00%Risk Discount Rate 13.00%Tax rate 14.2% (12.5% plus 10% surcharge

+3% education cess)

19

MNYL – Growth Strategy

*Growth rate calculated on Individual Adjusted Premium(Individual Non-Single Premium + 10% of Individual Single Premium)

AFYP Rs. 8,000 Croreby FY 11-12

15 Mn Policyholdersby FY 11-12

200,000 Agentsby FY 11-12

Over 100 offices every year,1,000 offices by FY 11-12

20

n MNYL would continue to be an agency led multi-channel distribution company. Keyfocus areas in distribution would be:

Grow agency and rural offices to build large geographic footprintSegment agency to build profitable scaleStrengthen and expand bancassurance and partnership distributionBuild scale in direct sales and exploit telemarketing capabilities

n Launch a new operating model to reach 100 millionlow income, under-serviced households, through

Successful Pilot done in Allahabad and Andhra PradeshActivated 20+ retail distributors in UPMajor tie up done with 2 MFI & 2 NGOsReady to establish 50,000 Point Of Sales by year endInitiated business partnerships with large format retailers including Reliance Retail, 3iInfoTech, Tata Capital to leverage their existing customers and POS relationships.

n Focus on health and retirement product segments to diversify the portfolio and fuelgrowth

n Enhance sales through cross-sell and up-sell to our growing customer base

n Improve MNYL brand awareness to support business expansion throughcomprehensive brand building agenda

MNYL – Growth Strategy

21

www.maxhealthcare.in

Max Healthcare [ MHC ]

22

Indian Healthcare

Indian Healthcare industry expected to grow at a 15%

CAGR till 2012 to contribute 6.1% of GDP

Key Driversn Key changes related to lifestyle and chronic

disease patternsn Minimally Invasive Surgery, lower ALOS & safer

surgical procedures – encouraging demandn Deeper penetration of diagnostics and

healthcare servicesn Growing middle classn Changing spending patternsn Health Insurancen Medical value travel

Healthcare Industry 2012 – US$ 78.6 billion

n Revenue generated by private hospitalscurrently estimated at US$ 15.5 billion, likely toincrease to US$ 35.9 billion by 2012

n Industry expected to add 1 million beds by 2012– private sector to contribute 89% of these bedsat an investment of US$ 70 billion

Source: Medistat World Market Analysis, 2006; E&Y Report, 2007

Market Size

34 19 137 250

2100

India Brazil China Germany USA

(USD

Bn)

Healthcare Industry 2012 - US$ 78.6 Bn

Bed Revenue, 36%

Health Insurance, 5%

Infrastructure, 14%

Others, 18%

Training & Education, 3%

Pharma and Consumables,

21%

Clinical Trials, 1%

Medical Value Travel, 2%

23

Enable retention of patient trafficEnable ‘start-to-finish’ comprehensive, seamless care: Consult and Diagnostics,

Diagnostic tests, surgeries, post-surgical care

MHC – Model

TERTIARYn Max Heart and Vascular Instituten Max Super Speciality Hospital

Heart and VascularNeurosciencesJoint Replacement and OrthopaedicsAesthetics and Reconstructive surgeryOncology

SECONDARY

PRIMARY

n Max Hospitals – 4n Speciality Centres – 2

n Clinics / Implants – 10

Surgery and inpatient facilitiesMother and ChildHigh-end diagnostics: MRI, CTDoctor consultationEye and Dental care

Specialist doctor consultBasic diagnostics like pathology collection

24

n Comprehensive world-class healthcare services

n State-of-the-art infrastructure and facilities

n Established brand name with leading specialist doctors

n Trained and anchored resources

n Leadership in key super-specialties in tertiary careCentres of excellence in cardiac, orthopaedics and joint replacement, neurosciences,paediatrics, obstetrics & gynaecology and aesthetic & reconstructive surgery

Organ transplant, oncology, cord blood banking, stem cell research to be added

n Extensive emphasis on medical training and educationDNB (Diplomate of National Board) & fellowship programs

High quality nursing and paramedic care supported by nursing and paramedic college

MHC – Key Differentiators

25

Healthcare facilities 8

Physicians 1,200*

Other support staff 3,000

Patient base Over 700,000

Patient transactions Over 160,000 pm

Beds 800

ICU beds 225

OTs 20

Cathlabs 3

MRIs 4

CTs 4

MHC – Key Highlights

*Includes over 500 physicians on Rolls

Fact Sheet Shareholding Pattern

Max India Limited70.1%

Others6.0% Warburg Pincus

20.1%IFC, Washington3.8%

Number of outstanding shares 237,094,548

Both the tertiary care hospitals are NABH accredited Lab facilities at Max Super Speciality Hospital are NABL accredited

26

MHC – Key Highlights

The business has turned Cash Positive …

*Average revenue per occupied bed day has been calculated on inpatient revenue

ALOS – 3.3 days

27

MHC – Second Phase of Expansion

n Around 255 bedsn Launch expected by October 2009n Tower specialties – oncology, cardiac

care, orthopaedics, neurosciences andcritical care

Tertiary CareMax Balaji Hospital – Patparganj

Max Hospital – Saket [South Block]

n Around 90 bedsn Launch expected by April 2010n Tower specialty – oncology

n Around 150 beds n Launch expected by April 2010n Cardiac Caren Orthopaedics and Joint replacementn Minimally Invasive Surgeryn Critical Care

National Capital Region

Outside National Capital Region

Tertiary Care Multi-SpecialityMax Hospital – Dehradun

Bed capacity to double to over 1500 beds by 2011

Land already in place for the second phase of expansion

Max Hospital – Greater Noida

n Around 300 Bedsn Launch expected by April 2012

Tertiary Care / Multi-Speciality

Max Hospital – Shalimar Bagh

n Around 300 Bedsn Launch expected by April 2011

Tertiary Care / Multi-Speciality

28

MHC – Project Funding

Project CostRs. 1,330 Crore

EquityCapital

Rs. 630 Crore

PreferenceCapital

Rs. 250 Crore

n Max IndiaCurrent – Rs. 166 CroreFuture – Rs. 54 Crore

n Warburg Pincus – Rs. 140 Croren IFC, Washington – Rs. 50 Croren Other Foreign Investors – Rs. 20 Croren To be tied up – Rs. 200 Crore

n Indian Banks and FinancialInstitutions

Current – Rs. 281 CroreFuture (tied-up) – Rs. 74 CroreTo be tied up – Rs. 95 Crore

Debt Funds

Rs. 450 Crore

n IFC, Washington

29

Max Neeman Medical International [ MNMI ]

www.neeman-medical.com

30

Revenue Mix - Clinical Trials

Phase-IV10%

Phase-III30%

Phase-II40% Phase-I

20%

Indian Clinical Research Industry

Key Driversn Huge patient population base

with therapeutic diversity

n Cost arbitrage

n Huge talent pool

n Data processing infrastructurefor bio-informatics

n Favorable patent regulationsto catalyze exponential growthand improving

Need availability gap in years to come

2001 2005 2010 (Projected)No. of trials 142 600 6,000Investigators 46 250-300 4,000-5,000Trained manpower 200 3,000 50,000

Study Sites Metros only

A class cities, few B class towns

All A class towns, many B and

C class towns

Source: E&Y Report, 2007; Thomson CentreWatch Analysis, 2007

Industry projected to grow to US$ 1.3 billion by 2012...

Indian clinical trials industry - US$ 265 million

31

MNMI – Contract Research Organization

n Service offerings include…Project managementMonitoringSite managementData management, includes bio-statistics and report writingClinical trial material supply chain management

n Confirmed order book of Rs. 40 Crore; BD pipeline of Rs. 120 CroreBD efforts focused on medium and small-sized biotech and pharma companies

n Strong operating performance…Continues to be profitableRevenue for the nine months ended Dec’08 more than double to Rs. 10 Crore.Patient retention rate maintained at 98%4 successful US FDA auditsDatabase of 830 GCP/ICH principal investigators

32

MNMI – Select List of Clients

33

Max Speciality Products [ MSP ]

www.maxindia.com

3434

Global BOPP IndustryKey Driversn Global flexible packaging industry – US$ 50

bn, of which BOPP Films contribute 70%

n Growth of flexible packaging Industry ~ 15%in India & 7 to 8% Globally

n Competitive advantage of BOPP films overother plastics and traditional products

n Shift from PET to BOPP. (Indian BOPP:PETproducts ratio around 1:2 against 3:1 globally)

n BOPP films in strong demand from consumergoods industries

n Organised retail and changing urban lifestyles to further expand demand for BOPPfilms

n Competitive cost advantage for exportmarkets

BOPP per capita consumption in India lower than

the global average

Source: AMI & Access

Global Per Capita Consumption of BOPP Film

1.9

1.2

0.50.4

0.30.1

0.4

WesternEurope

NorthAmerica

Asia LatinAmerica

EasternEurope

India WorldAverage

KG

35

Max Speciality Products is much more than packaging…n Manufacturer of niche (high margin) and high barrier speciality polymer films

n Pioneer in introduction of value added products / technology in India

n Long term relationship with blue chip customers

MSP – Key Differentiators

Commodity Speciality(Preferred)

End UsePackaging,Industrial,

Textiles

Packaging,Lamination

MetallisedFilms Coated Films Foils

Packaging,Lamination,Industrial,

Packaging, Industrial

Lifestyle,Apparels

Our Focus

36

MSP – Key Highlights

*9M’FY09 numbers have been annualised by a factor of 0.75 to reflect FY09 numbers.

Track Record of Strong Performance…

n BOPP lines of 29,000 TPA running at 100% utilization

n Return on Capital Employed for the nine months ended December 2008 at 15%

n Third thermal line with a capacity of 10,000 KSM expected to be operational by Mar’09

n Leather finishing foil business to more than triple its capacity to 5000 KSM by Mar’09

n Planning fourth BOPP production line with a capacity of 20,000 TPA in early 2010

37

Thank You

38

Max India – Management Team

Mr. Analjit Singh

Chairman & Managing

Director

Mr. Analjit Singh has been the driving force behind Max Group’s sustained growth and success since the early 80’s. Mr.

Singh a prominent industrialist is an alumnus of Doon School; University of Delhi, and the Graduate School of

Management, Boston University

Mr. C. V. Raghu

Director – Legal &

Regulatory

Mr. Raghu brings with him a rich and varied experience of 22 years, of which, 14 years have been spent with American

Express Bank. Prior to that, he has worked with Hindustan Lever Limited and CII. He holds a Bachelors Degree in Law

from Faculty of Law, Delhi University.

Ms. Kirti Madhok Sud

Director – Corporate

Support

Ms. Sud brings rich and varied experience of about 27 years in the banking sector with Citibank, ICICI and ANZ

Grindlays; a free lance correspondent for the Economist Magazine Group and an independent business owner with

Amway India. She holds a Bachelors Degree in Economics (Honours) and an MBA from IIM, Ahmedabad.

Mr. Mohit Talwar

Director – Corporate

Development

Mr. Talwar brings rich and varied experience of 28 years with The Oberoi hotels, Bank of Nova Scotia, Grindlays &

Standard Chartered. In his last assignment with Standard Chartered he was responsible for developing strategy,

revenue & economic profit across products. Mr. Talwar is a post-graduate in Arts and Hospitality Management.

39

Max India – Management Team

Mr. P. Dwarakanath

Director - Group

Human Capital

Mr. Dwarakanath brings rich and varied experience of 37 years primarily from GSK GlaxoSmithKline Consumer

Healthcare and is currently the non Executive Director of GSK. He has done his Post Graduate diploma in Personnel

Management and Industrial Relations, B.Sc and Bachelor of Law.

Ms. Sujatha Ratnam

Chief Financial

Controller

Ms. Ratnam brings with her over 15 years of rich and varied experience with Jubilant Organosys and Tata Motors and

has expertise in the field of financial restructuring and fund raising. She is a Chartered Accountant.

Mr. V Krishnan

Company Secretary

Mr. V. Krishnan has more than 18 years of rich experience in Corporate Regulatory and Compliance matters and has

been closely involved in establishing joint ventures, mergers & acquisitions and business restructuring of Max Group.

He is a member of the Institute of Company Secretaries of India.

40

MNYL – Management Team

Mr. Rajesh Sud –

Managing Director

and CEO

Mr. Sud, a founder member, has been instrumental in establishing MNYL’s distribution footprint across India. Today

MNYLs Agency model is recognized as “best-in-class”. Prior to joining MNYL, he was the CEO & Managing Director of

Esanda Finance Ltd (a financial services subsidiary of ANZ Grindlays Bank)

Mr. Rajit Mehta –

Chief Operating

Officer

Mr. Mehta, a founder member, has led and built the HR function of MNYL and provided overall HR direction in line with

business strategy. He has also played a significant role in managing change / transition agendas both at a functional

and organizational level while facilitating strategic initiatives. Prior to joining MNYL, he was Director - Human Resources

at Bank of America, India

Mr. John Poole

Chief Actuary

Mr. Poole, is both Chief Actuary and Appointed Actuary for MNYL. He has been instrumental in building MNYLs

actuarial capability and implementing best practices. Prior to this assignment, he worked with AMP in various key

management positions including CFO and Actuary

Mr. Sunil Kakar

Senior Director &

Chief Financial Officer

Mr. Kakar joined MNYL in March 2001 and is in charge of Finance, Accounts, Investments and Risk Management.

Under his leadership investment portfolio continues to generate top quartile returns. Prior to joining MNYL, Sunil was

with Bank of America, India as Vice President (CFO)

41

ExcellenceHonestyKnowledge

MNYL – Road Map to Becoming India’s Most Admired Life Insurance Company

Key Public Messages

A trusted life insurance specialistCustomer centricFinancially responsible and strongA great place to workAn admired member of the community

VISION Become the most admired Life Insurance Company in India

MISSION

GOALS3 Billion $ in Premiums in 10th yearIRR–20% plus; Dominate MDRT in India; Profitable by FY 11-12

KEY

OBJECTIVES

STRATEGIES

WHAT – Comprehensive suite of products, competitive pricing, extensive distribution, persistency, customer service excellence, profitable portfolios

HOW – Talented People, Professional & Productive Agents, Performance Metrics, Leverage Technology, Teamwork, Customer Centric, Innovative Distribution and Marketing

INITIATIVESWhat-When-Who-How-Cost linkage plans at Departmental and Individual levels

VALUES & BELIEFS OPERATING PRINCIPLES METRICS & STANDARDS

PERFORMANCE MGMT PROCESS

Caring IntegrityTeamwork

Customer comes firstInternational quality standardsDo it right the first timeFact based decisionsBias for result oriented actionFinancial strength & disciplineDirect and open communicationRespect Max & NYLI values & parentageFun at work

InputOutputExternalInternalAbsoluteRatios

GMPR RatingsTEC/TTR – TemplatesPrimary, Shared and ContributoryBalanced scorecardCore, Functional and Leadership Competencies

Part of top quartile new Life Insurance CompaniesNational PlayerBrand of FIRST choiceEmployer of ChoicePrincipal of Choice for Agents

Key DifferentiatorsFinancial Strength & SecurityQuality of agentsFlexible ProductsService ExcellenceFair Terms of Business

US$ 1 = INR 49

42* Conservation Ratio = Renewal Premium for the current period / (First Year+Renewal Premium for the previous period)

MNYL – Key HighlightsKey Business Drivers Unit Quarter Ended Y-o-Y

Growth

Nine months Ended Y-o-Y Growth

Dec-08 Dec-07 Dec-08 Dec-07

a) Sales Value (Annualized first year premium) Rs. Crore 547 478 14% 1,578 1,103 43%

b) Average case size Rs. 17,877 23,230 -23% 19,500 22,427 -13%

c) Case rate per agent per month No. 1.15 1.70 -32% 1.13 1.44 -22%

d) Number of agents No. 72,226 29,904 142%

e) Net agents added No. 13,645 1,330 35,330 4,856

f) Conservation ratio* % 80% 80% 85% 82%

g) Gross written premium income Rs. Crore

First year premium 377 354 6% 1,176 848 39%

Renewal premium 541 318 70% 1,333 726 84%

Single premium 61 92 -34% 194 189 3%

Total 978 764 28% 2,703 1,763 53%

h) Paid up Capital Rs. Crore 1,782 907 96%

i) Individual Policies in force No. 2,416,721 1,500,589 61%

j) Sum insured in force Rs. Crore 93,575 62,600 49%

43

MHC – Management Team

Dr. Pervez Ahmed

CEO and Managing

Director

Dr. Ahmed has been an active participant in healthcare related fields especially development of standards of critical

care medicine in New York. Since 1977 he has been involved in academic Medicine at SUNY, Downstate. He has

also been involved in many healthcare activities in India dating back to 1980. Dr. Pervez Ahmed, MBBS from AFMC,

Pune, has completed Residency in Internal Medicine and Fellow-ship in Cardiology in New York. He is Board certified

in Internal and Cardiovascular disease and a Certified Medical Director.

Mr. Arvind Kakar

Vice President Finance

Mr. Kakar is a Chartered Accountant with over 18 years of experience in service industries and having a high focus in

the areas of financial services and healthcare. He has been associated with the Max group since 2000.

Mr. Sanjay Rai

Director Marketing &

Customer Management

Mr. Rai brings with him more than 28 years experience in Sales & Marketing in service and manufacturing industries.

He has earlier worked with The Oberoi group and ITC Limited. He leads and manages various sales channels at Max

Healthcare and is also responsible for Branding, Customer Relationship Management and Direct marketing, PR

function and for service excellence. He is an graduate in Economics from Mumbai University,

Dr. D. P. Saraswat

Regional Director

Dr. Saraswat has rich and varied experience of 36 years including 22 years in the Indian Army where he held Lt. Col.

rank. Thereafter he continued his career with Manipal Hospital as COO & Medical Director. He also held the position

of Head & Professor Dept. of Hospital Administration in Manipal University. He is M.B.B.S from S. N. Medical College,

Agra and MHA from A F M C, Pune.

Dr. Dilpreet Brar

Regional Director

Dr. Brar was associated with the Indraprastha Apollo Hospitals and Hero Honda group of companies prior to joining

Max Healthcare in 2002. She is responsible for business operations of Saket, Panchsheel and Gurgaon Hospitals. Dr.

Brar is a graduate from Govt. Medical College, Patiala. She secured a post graduate diploma in hospital management,

and completed a certificate course in Health Insurance from Indraprastha Apollo hospitals, New Delhi.

44

Padma Shri Dr. Rustom Phiroze Soonawala

MD, FRCS, FRCOG

Chairman, Obstetrics & Gynaecology

Eminent and Internationally renowned Obstetrician & Gynaecologist.

Former President of the Federation of Obstetricians and Gynaecologists

Dr. Praveen Chandra

MD, DM,FAPSIC, FACC, FSCAI, FESC

Director – Cardiac Cath Lab

Internationally Renowned Cardiologist.

First to use new devices like Rotarex,Kensey Nash DPD in the country.

Dr. S.K.S. Marya

M.S., DNB, Mch, FICS

Director – Max Institute of Orthopedics & Joint

Replacement

Renowned Joint Replacement Surgeon having 30 years experience.

Pioneered bilateral Hip and Knee Joint replacement.

Author and teacher par excellence.

Dr. Ajaya Nand Jha

MS, FRCS

Director – Max Institute of Neurosciences

Renowned Neurosurgeon with rich and varied experience including

stints with Manchester Royal Infirmary, P.D. Hinduja National Hospital,

Indraprastha Apollo Hospital.

First to use image guided Neurosurgery in the country.

First to use dedicated X-knife (Radiosurgery) and intra-operative MR

with image guidance for Brain Tumour Surgery.

Dr. Arvind Taneja

MD, FAAP

Director, Paediatric Services

Specialised in treating Paediatric Infectious Diseases

Awarded ‘Best Paediatrician’ of Delhi

Winner of several awards. Ex-teacher PGI Chandigarh and AIIMS.

MHC – Key Physicians

45

VISIONDeliver world class healthcare with a service focus, by creating an institution committed to the highest standards of medical & service excellence, patient care, scientific knowledge and medical education.

MISSION

GOALS• Profitable without profiteering.• Seamless linkage between secondary and tertiary care.• Innovate to address wider market.

KEY OBJECTIVES

STRATEGIES

WHAT – Medical USP’s ; Best in class ; Comprehensive care ; Convenience & accessibility ; Seamless service ; Patient records ; Consistent and customised care ; Service excellence ; Preventive health ; Caring place to work.

HOW – Train train train ; Partnership with Medical community ; Principal choice for physicians ; Never ending focus on medical and service excellence ; Build lasting customer relationships ; Primary, Secondary and Tertiary care through Co. managed / partnership; No franchising.

VALUES & BELIEFS OPERATING PRINCIPLESMETRICS &

STANDARDSPERFORMANCEMGMT PROCESS

• Create unparalleled standards of Medical & Service Excellence• Care provider of FIRST CHOICE• Principal Choice for Physicians• Ethical Practices • Create National Centre of Excellence for select Super Specialties.• Build towards international ‘reach’ by creating patient confidence through

professional skills, research and technology

• Competence rating• Potential analysis• PSC model• Balanced scorecard• Performance / Risk linked

reward.

• Caring • Excellence• Integrity

- Personal- Professional

• Openness/Transparency• Teamwork• Knowledge • Win-win partnerships

• Courtesy & Caring always• Customer comes first• Do it right first time• International image standards• Efficient process management• Direct & open communications • Create trust• Fun at work• Compliance

• ISO 9001 : 2000• JCIA Accreditation• Credentialing / Grant

of privileges• Employee productivity• Employee Engagement survey• Service Dashboard - Sparsh• NABH Accreditation• NABL certified Lab system.

INITIATIVES• WHAT- HOW - WHEN - COST - LINKAGE• Shared responsibility with single accountability.• Unique approach through: - International benchmarking. - Walk the Talk - IT Capability- Medical – Management Alignment. - Rehearse rehearse - Cost Efficiency- Train train train. - Mystery customers - Attrition Management

MHC – Vision / MissionBuild TrustPASSIONKey Differentiators

Focused NCR centric delivery – for operational excellenceClose to customer – geographyComprehensiveness of medical services (except organ transplant and radio therapy)Leadership in 5 super-specialties in tertiary care-‘Star’ physicians supported by a group of high quality physiciansEthicsMemorable brand experience-‘Star’ and quality physicians-Infrastructure and equipment-No surprises – cost of care, pricing, medication-Signage-Look – feel – smell - touchInnovation to bring in walk-in customers-Location-Max Health Plan-Other new programs i.e. Golden Years, Life Membership, PrepaidHigh quality nursing and paramedic care supported by nursing and paramedic collegeExtensive emphasis on training

Key Public MessagesMedical ExcellenceService Excellence – Total ExperienceIn your community - near youHigh-end tertiary care in Private

sectorComprehensivenessReferral system – National & International

Value for moneyPartnering with medical communityCaring place to work Corporate Social Responsibility

46

Express Healthcare Excellence Awards (2007 – 08)

MHC – Accreditations and Awards

“Innovative Marketing Practices”

“Best Managed Healthcare Program (Health Insurance/TPA)”

First in North India to get NABH on Feb. 6th, 2007

47

MHC – Key HighlightsKey Business Drivers Unit

Quarter Ended Y-o-Y Growth

Nine Months Ended Y-o-Y Growth Dec-08 Dec-07 Dec-08 Dec-07

a) Revenue Rs. CroreInpatient Revenue 80.4 80.2 0% 245.4 220.7 11%Outpatient Revenue 22.6 17.8 27% 68.7 51.4 34%Total 103.0 98.0 5% 314.1 272.1 15%b) ProfitabilityContribution Margin Rs. Crore 59.5 50.6 18% 177.4 143.5 24%Contribution (%) % 57.8% 51.6% 56.5% 52.7%EBITDA Rs. Crore 8.4 5.2 62% 23.6 13.0 82%EBITDA (%) % 8.2% 5.3% 7.5% 4.8%Cash Profit Rs. Crore 1.7 (1.7) 1.8 (11.5)c) Patient Transactions No.Number of Procedures- Cardiac Care 1,593 1,911 -17% 5,406 5,583 -3%- Orthopaedics 514 476 8% 1,619 1,513 7%- Neurosciences 249 187 33% 662 552 20%- Obstetrics & Gynaecology 1,230 1,095 12% 3,633 3,118 17%- Others 2,289 2,098 9% 7,154 6,095 17%Medical Admissions 6,616 6,385 4% 20,010 17,713 13%Outpatient Registrations 444,344 407,397 9% 1,416,965 1,169,734 21%d) Average Operational Beds No. 714 674 6% 709 657 8%e) Average Occupancy % 62.9% 67.9% 65.8% 66.0%f) Average Length of Stay No. 3.3 3.5 3.3 3.4 g) Average Revenue per Occupied Bed Day Rs. 19,464 19,034 2% 19,119 18,503 3%

48

MAX HEART & VASCULAR INSTITUTE(December 2004)n 200 patient bedsn 3 OTs, 2 Cardiac Catheterization Labsn Post Surgery Critical Care Unitn High Dependency Unitn Apex and Advanced Coronary Caren Exclusive well equipped ‘Observation Bay’ and

‘Post Cath. Recovery’n Nuclear Diagnostic Services with Variable Angle

Dual Head Gamma Cameran Centralized Emergency Command with

Advanced Cardiac Life Support Ambulances andAir Evacuation Service

n High-end General Surgery

MAX SUPER SPECIALITY HOSPITAL(May 2006)n 191 beds (including 63 critical care beds)n 7 OTs, 20 Consult Chambersn Tower Specialties – Orthopaedics, Neuro

Sciences, Obstetrics & Gynaecology, Paediatricsand Aesthetic & Reconstructive Surgery

n Brain Suite (first in Asia) and Intra Operative MRIn DSA Lab (for Neuro Sciences)n Emergency Servicesn High end Radiology facilities with 64 slice Cardiac

CT

MHC Tertiary Care Facility, Saket [South Delhi]

49

PITAMPURA(February 2002)(North Delhi)

90 inpatient beds2 OTsLithotripsyMother and child careNon-invasive cardiologyPlastic and reconstructive surgeryPhysiotherapyFull range diagnosticsPHP, OPD and Dentistry

PATPARGANJ(May 2005)(East Delhi)

154 inpatient beds3 OTsMother and child careOrthopaedicsGeneral surgeryCritical care including dialysisNon-invasive cardiology (incl. cardiac catheterization lab)ENT, ophthalmologyOther allied specialties

MHC Secondary Care Facility [ Delhi ]

50

MHC Secondary Care Facility [ Suburb of Delhi ]

NOIDA(August 2002)

33 inpatient beds2 OTsMother and child careNon-invasive cardiologyLaparoscopic surgeryOrthopaedicsENT, ophthalmologyUrology and nephrologyFull range diagnosticsPHP, OPD and Dentistry

GURGAON(July 2007)

102 inpatient beds 3 OTsOphthalmology (anterior and posterior)Woman and child (including infertility)Medical & surgical intensive careOrthopaedicsNephrology and urologyAesthetic and reconstructive surgeriesGeneral and minimally invasive surgeriesPHP and OPD

51

MHC Speciality Centres – Panchsheel [South Delhi]

OPTHALMOLOGY AND DENTAL CARE(November 2005)

Lasik, OPD and diagnosticsDental – 3 chambersSupport services and offices

SPECIALIST CONSULTS AND HIGH-END DIAGNOSTICS (August 2006)

GP and specialist consultsDiagnosticsNeurology (EEG and EMG)Preventive health and chronic carePhysiotherapyMinor procedures and emergenciesIVF

52

MSP – Performance Snapshot

Key Business Drivers Unit Quarter EndedY-o-Y

Growth

Nine Months EndedY-o-Y

Growth

Dec-08 Dec-07 Dec-08 Dec-07

a) Sales Quantity - BOPP Tons 7,155 6,655 7% 20,988 16,749 25%

b) Revenue Rs. Crore 80.2 84.0 -5% 285.1 214.4 33%

c) Profitability:

Contribution Margin* Rs. Crore 32.2 32.3 0% 100.9 82.6 22%

% 40.1% 38.5% 35.4% 38.5%

EBITDA Rs. Crore 10.3 13.4 -23% 38.2 32.8 16%

% 12.8% 16.0% 13.4% 15.3%

PBT Rs. Crore 3.5 7.3 -52% 17.9 14.5 23%

% 4.4% 8.7% 6.3% 6.8%

53

DisclaimerThis presentation has been prepared by Max India Limited (the “Company”). No representation or warranty, express or implied, is made and no

reliance should be placed on the accuracy, fairness or completeness of the information presented or contained in the presentation. The past

performance is not indicative of future results. Neither the Company nor any of its affiliates, advisers or representatives accepts liability

whatsoever for any loss howsoever arising from any information presented or contained in the presentation. The information presented or

contained in these materials is subject to change without notice and its accuracy is not guaranteed.

The presentation may also contain statements that are forward looking. These statements are based on current expectations and assumptions

that are subject to risks and uncertainties. Actual results could differ materially from our expectations and assumptions. We do not undertake

any responsibility to update any forward looking statements nor should this be constituted as a guidance of future performance.

This presentation does not constitute a prospectus or offering memorandum or an offer to acquire any securities and is not intended to provide

the basis for evaluation of the securities. Neither this presentation nor any other documentation or information (or any part thereof) delivered or

supplied under or in relation to the securities shall be deemed to constitute an offer of or an invitation.

No person is authorised to give any information or to make any representation not contained in and not consistent with this presentation and, if

given or made, such information or representation must not be relied upon as having been authorised by or on behalf of the Company any of

its affiliates, advisers or representatives.

The Company’s Securities have not been and are not intended to be registered under the United States Securities Act of 1993, as amended (the

“Securities Act”), or any State Securities Law and unless so registered may not be offered or sold within the United States or to, or for the

benefit of, U.S. Persons (as defined in Regulations S under the Securities Act) except pursuant to an exemption from, or in a transaction not

subject to, the registration requirements of the Securities Act and the applicable State Securities Laws.

This presentation is highly confidential, and is solely for your information and may not be copied, reproduced or distributed to any other

person in any manner. Unauthorized copying, reproduction, or distribution of any of the presentation into the U.S. or to any “U.S. persons” (as

defined in Regulation S under the Securities Act) or other third parties ( including journalists) could prejudice, any potential future offering of

shares by the Company. You agree to keep the contents of this presentation and these materials confidential.

54

MAX INDIA LTD.Max House, Okhla, New Delhi – 110 020

Phone: +91 11 26933601-10 Fax: +91 11 26933619Website: www.maxindia.com